Dr Reddys Laboratories (RDY) Common Equity (2012 - 2026)

Dr Reddys Laboratories' Common Equity history runs 15 years deep, the most recent figure standing at $4.1 billion for Q1 2026.

• In Q1 2026, Common Equity rose 7.14% year-over-year to $4.1 billion; the TTM figure through Mar 2026 stood at $4.1 billion (up 7.14% YoY), while the FY2026 annual figure was $4.1 billion, up 3.87% from the prior year.
• Common Equity was $4.1 billion for Q1 2026 at Dr Reddys Laboratories, down from $4.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $4.2 billion in Q3 2025 to a low of $2.5 billion in Q1 2022.
• Historically, Common Equity has averaged $3.4 billion across 5 years, with a median of $3.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity climbed 4.2% in 2022, then gained 20.61% in 2024.
• A 5-year view of Common Equity shows it stood at $2.6 billion in 2022, then increased by 18.36% to $3.1 billion in 2023, then increased by 20.61% to $3.7 billion in 2024, then rose by 12.42% to $4.2 billion in 2025, then declined by 0.64% to $4.1 billion in 2026.
• The last three Common Equity figures came in at $4.1 billion (Q1 2026), $4.2 billion (Q3 2025), and $3.8 billion (Q1 2025), per Business Quant data.